Invention Grant
US08344008B2 Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase
有权
芳基取代的桥连或稠合二胺作为白三烯A型调质剂
- Patent Title: Aryl-substituted bridged or fused diamines as modulators of leukotriene A ydrolase
- Patent Title (中): 芳基取代的桥连或稠合二胺作为白三烯A型调质剂
-
Application No.: US13091498Application Date: 2011-04-21
-
Publication No.: US08344008B2Publication Date: 2013-01-01
- Inventor: Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alexandro Santillán, Jr.
- Applicant: Genesis M. Bacani , Scott D. Bembenek , Wendy Eccles , James P. Edwards , Matthew T. Epperson , Laurent Gomez , Cheryl A. Grice , Aaron M. Kearney , Adrienne M. Landry-Bayle , Alice Lee-Dutra , Kelly J. McClure , Taraneh Mirzadegan , Alexandro Santillán, Jr.
- Applicant Address: BE Beerse
- Assignee: Janssen Pharmaceutica NV
- Current Assignee: Janssen Pharmaceutica NV
- Current Assignee Address: BE Beerse
- Main IPC: A61K31/425
- IPC: A61K31/425
Abstract:
Aryl-substituted bridged or fused diamine compounds, pharmaceutical compositions containing them, and methods of using the compounds and the pharmaceutical compositions for leukotriene A4 hydrolase (LTA4H or LTA4H) modulation and for the treatment of disease states, disorders, and conditions mediated by LTA4H activity, such as allergy, asthma, autoimmune diseases, pruritis, inflammatory bowel disease, ulcerative colitis, and cardiovascular disease, including atherosclerosis and prevention of myocardial infarction.
Public/Granted literature
- US20110257153A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase Public/Granted day:2011-10-20
Information query
